Merck's Zocor
Executive Summary
Cholesterol-lowering drug will be a primary HMG-CoA reductase inhibitor for Kaiser Permanente Medical Care Program members under a "long-term. agreement" between Merck and the HMO. Merck's other HMG-CoA reductase inhibitor, Mevacor, retains its primary listing under the new agreement